0.00Open1.50Pre Close0 Volume35 Open Interest12.50Strike Price0.00Turnover53.63%IV0.72%PremiumDec 20, 2024Expiry Date1.42Intrinsic Value100Multiplier21DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type-0.8027Delta0.2006Gamma3.79Leverage Ratio-0.0084Theta-0.0046Rho-3.04Eff Leverage0.0074Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet